Long-distance running is one of the most widespread individual sports modalities and have become even more popular in the last decade (Hagan, 2018). Long-distance running promotes several systemic and muscle adaptations (Li et al., 2019), increases maximal oxygen uptake (V̇O2max) (Paavolainen, Nummela, & Rusko, 2000) and time to exhaustion (Hausken, 2019). The oxidative system demand of long-distance runners is about 3-fold higher compared with physically active people (Skovgaard et al., 2014; Vuorimaa, Häkkinen, Vähäsöyrinki, & Rusko, 1996) and a relative increase of type IIa at expense of type IIb, results in the ability to increased fat metabolism (Giovanelli et al., 2016). In consequence, long-distance running provokes a calcium imbalance, which results in inefficiency of muscular contraction (Pearcey et al., 2015). Therefore, different ergogenic and thermogenic compounds were strategically used to optimize performance in middle and long-distances running (Schubert & Astorino, 2013).
Capsiate (CAP) is an analog of capsaicin, belonging to an 8-methyl-N-vanillyl-trans-6-nonenamide natural phytochemical compound found primarily in red peppers (Ludy, Moore, & Mattes, 2012) and also in the analog of a sweet pepper species (CH-19 sweet) which has the same molecular structure as capsaicin, except for the substitution of NH for O in the alkyl chain that alters the pungency factor (Ohnuki et al., 2001). This phytochemical has been used as a nutritional strategy to improve performance in different intensities and exercises distances (de Freitas, Billaut, et al., 2019; de Freitas et al., 2018). The dose of capsaicin in studies remains not well established for humans. Previously studies from our research group have used 12 mg of CAP 45 minutes before the exercise trials and there was found an improvement in performance for short duration aerobic exercise (Costa et al., 2020; de Freitas, Billaut, et al., 2019; de Freitas et al., 2018) and in combined exercise protocol (5-km running plus strength exercise), was 24 mg of CAP in two doses of 12 mg with 45 minutes interval between doses (de Freitas, Cholewa, et al., 2019). On the other hand, another study used a dosage of CAP of 150 mg administrated 60 minutes before exercise protocol (30 minutes of aerobic exercise at 50% of maximal ventilatory threshold on a stationary ergometer), shows a better endurance performance, demonstrating higher fat oxidation during exercise under CAP condition compared to placebo condition (Shin & Moritani, 2007). Therefore its already known that the peak concentration of CAP occurs around 45 minutes after ingestion and bioavailability is approximately 25 minutes, so it is in the plasma for up to 105 minutes (Chaiyasit, Khovidhunkit, & Wittayalertpanya, 2009; Rollyson et al., 2014).
In skeletal muscle, CAP phosphorylates the transient vanilloid-1 receptor (TRPV1), which results in the release of available calcium in the sarcoplasmic reticulum, optimizing the myosin-muscle actin interaction, consequently improving the processes of force generation and optimizing the efficiency in depleting intramuscular triglycerides and preserve muscle glycogen, thus increasing the time to exhaustion (Lotteau, Ducreux, Romestaing, Legrand, & Van Coppenolle, 2013). Moreover, TRPV1 is activated in the putative pain neural circuit (Watanabe, Kawada, Kurosawa, Sato, & Iwai, 1988) increasing fat metabolism, at least in part, due to β-adrenergic stimulation induced by CAP supplementation. Therefore, the CAP ingestion may increase fat metabolism by both stimulating lipolysis and inhibiting lipogenesis (Yoshioka et al., 1995), which could potentiate longer distance performance.
Regarding the potential ergogenic effect of CAP, previous studies from our research group demonstrated that 12 mg of acute CAP supplementation was effective to improve a 1.500 meters running time-trial performance with a lower rate of perceived exertion (RPE) (de Freitas et al., 2018). Recently, an investigation about running performance and CAP verified the effect of acute CAP supplementation on short (400-meter) and moderate distance (3000-meter) running time trial performance in physically active men but they did not find differences for heart rate (HR) and RPE (Costa et al., 2020). Despite several studies have been conducted investigating the potential effect of CAP on performance mainly in rodents (Kim, Park, & Lim, 2016), short and moderate distances (de Freitas et al., 2018; Yoshioka et al., 1995) or high-intensity intermittent exercises in human (de Freitas, Billaut, et al., 2019; Opheim & Rankin, 2012) there is no evidence of CAP supplementation effects during long-distance running, such as 10-km time-trial. Furthermore, previous studies at the literature demonstrating the benefits of CAP on performance were conducted in physically active men, therefore, it is a lack of study investigating the effect in experienced runners.
Thus, the objective of this study was to verify the acute effect of CAP supplementation on 10-km running time trial performance and physiological responses in amateur athletes. We hypothesize that acute CAP supplementation could be a ergogenic strategy to improve long-distance performance (10-km) with lower lactate concentration, HR and RPE in this athletes compared to placebo condition.